Skip to content
Companies

Caspian Therapeutics

Menin inhibitors to restore insulin production

Raised to date

$50M

of $50M offered across 1 Form D filing

Investors
43
Last filed
Sep 23, 2026

About

Caspian Therapeutics is a San Diego biotech spun out of Kura Oncology in September 2026 to develop small-molecule menin inhibitors as potentially disease-modifying therapies for diabetes and cardiometabolic diseases. Its lead compound, KO-7246, is a highly selective menin inhibitor designed for chronic metabolic use that aims to restore endogenous insulin production by expanding and improving the function of pancreatic beta cells. The company launched with a $50 million financing led by BVF Partners to take KO-7246 through IND-enabling work and initial clinical proof-of-concept.

Builds on more than a decade of Kura Oncology's menin-inhibition R&D; aims to modify diabetes by restoring beta-cell function rather than only managing blood glucose.

Funding

  • EquityFiled Sep 23, 2026Form D
    $50M/ $50M

Product

KO-7246

Small-molecule drug candidate (preclinical)

Next-generation, highly selective small-molecule menin inhibitor optimized for chronic metabolic disease; in preclinical models it selectively expanded pancreatic beta cells, increased insulin production and improved glycemic control in Type 1 and Type 2 diabetes models.

  • Highly selective menin inhibition
  • Preclinical beta-cell expansion and increased insulin production
  • Durable glycemic improvements persisting after treatment stopped in preclinical models

Built for

Patients with Type 1 and Type 2 diabetes and cardiometabolic disease

People on file